Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Almonty Announces Intention to Relocate to the United States (click to learn more) Benton Intersects 22.0 m Grading 7.47% Copper Including 8.0 m Grading 11.93% Copper (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PMGC Holdings Inc ELAB

Healthcare Medical Care
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. The Company’s portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the... see more

Recent & Breaking News (NDAQ:ELAB)

PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture

GlobeNewswire 4 days ago

PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries

GlobeNewswire 5 days ago

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

GlobeNewswire January 2, 2025

Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products

GlobeNewswire January 2, 2025

Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada

GlobeNewswire December 20, 2024

Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada

GlobeNewswire December 20, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation

GlobeNewswire December 9, 2024

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

GlobeNewswire December 6, 2024

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division

GlobeNewswire December 4, 2024

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

GlobeNewswire November 22, 2024

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

GlobeNewswire November 22, 2024

CORRECTION - Elevai Labs Inc.

GlobeNewswire November 14, 2024

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

GlobeNewswire November 14, 2024

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

GlobeNewswire November 4, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

GlobeNewswire October 22, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

GlobeNewswire October 21, 2024

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

GlobeNewswire October 4, 2024

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

GlobeNewswire October 3, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

GlobeNewswire October 3, 2024

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

GlobeNewswire October 2, 2024